Roche Chairman Severin Schwan criticized United States tariff policies on June 4, describing a drug-pricing agreement as "cold-blooded blackmail." The comments follow a late-2023 deal to cut medicine prices after officials threatened 200% tariffs on drugmakers. The rhetoric highlights escalating geopolitical risks for European pharmaceutical firms operating in major global markets.

The Pricing Conflict in Interlaken